Data demonstrating superior selectivity, safety and pharmacokinetics of RGT-0474060 were presented at the 21st Annual Huntington’s Disease ...

TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel ...

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology ...

The modulation of RNA splicing by small molecules has emerged as a promising strategy for treating pathogenic infections, human genetic diseases, and cancer; however, the principles by which splicing ...

Neuroendocrine tumors, including small cell lung cancer and neuroendocrine prostate cancer, are very aggressive with high chances of spreading. However, many individuals develop resistance to few ...

Akari Therapeutics is advancing its research on a novel spliceosome modulator, PH1, which has shown potential in killing cancer cells and activating the immune system. The company is focusing on the ...

RNA splicing is a cellular process that is critical for gene expression. After genes are copied from DNA into messenger RNA, portions of the RNA that don't code for proteins, called introns, are cut ...

This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ultimately halting the trial. The results of a clinical trial, called VIBRANT-HD, investigating an oral ...

Ipsen has swooped on a $1.8 billion R&D opportunity, joining with Skyhawk Therapeutics for the chance to option two candidates that could benefit from its “neuroscience expertise in movement disorders ...

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified ...

RNA splicing is a cellular process that is critical for gene expression. After genes are copied from DNA into messenger RNA, portions of the RNA that don't code for proteins, called introns, are cut ...